6 HD Insights, Vol. 12
SPONSOR STUDY
NAME/
IDENTIFIER
STUDY
AGENT
PHASE PRINCIPAL
INVESTIGATOR,
CONTACT
DESIGN TRIAL
LENGTH
SITES STATUS
Raptor
Pharmaceuticals
CYST-HD
Cysteamine
bitartrate
delayed-release
capsules (RP103)
II/III
Christophe Verny,
MD
Double-blind, placebo-controlled study to be
followed by an open-label extension study
36 months
8 total -
France
Enrollment
complete,
study ongoing
Auspex
Pharmaceuticals
FIRST-HD
SD-809
Extended
Release
III
Samuel Frank, MD
Huntington Study
Group: 800-487-7671
Randomized, double-blind study to determine
whether SD-809 ER tablets are effective in the
treatment of chorea associated with HD. To be
followed by an open-label, long-term safety study
12 weeks
7 total -
United
States
Study
complete, top
line results
released
Auspex
Pharmaceuticals
ARC-HD
SD-809
Extended
Release
III
Samuel Frank, MD
Huntington Study
Group: 800-487-7671
Open-label, long-term safety study of SD-809 ER
58 weeks
7 total -
United
States
Enrollment
complete,
study ongoing
Assistance
Publique -
Hôpitaux de
Paris
REVHD Resveratrol
III
Tiffany Monier, MS
+33 1 57 27 42 22
Randomized, placebo-controlled study to
evaluate the therapeutic potential of Resveratrol
on caudate volume in HD patients, using
volumetric MRI
1 year
1 total -
France
Currently
enrolling
Assistance
Publique -
Hôpitaux de
Paris
NEUROHD
Olanzapine,
Tetrabenazine,
and Tiapride
III
Anne-Catherine
Bachoud Levi, PhD
+33 (0)1 49 81 23 01
Randomized, controlled study to compare the
beneficial and adverse effects of 3 different
neuroleptics in HD
1 year
1 total -
France
Currently
enrolling
Copyright © Huntington Study Group 2015. All rights reserved.
Clinical Trials, cont...
To update or add a clinical trial, please e-mail editor@hdinsights.org.
Sources: www.clinicaltrials.gov and apps.who.int/trialsearch/
H D I N S I G H T S
Teva CNS is committed to continued research and development of its product portfolio and to the development of
medicines aimed at meeting the specific needs of the patient communities it serves. Teva's legacy in CNS is
grounded in its commitment to ongoing collaboration with academia, medical institutions and patient advocacy
groups to find innovative solutions for patients who live with chronic and debilitating diseases.
H D I N S I G H T S
T M
T H A N K S T E V A F O R I T S
G E N E R O U S S U P P O R T